Loading
A phase 3 trial of Docetaxel, Epirubicin, Cyclophosphamide, Fluorouracil, Lenograstim and Pegfilgrastim in Breast cancer, run by Hellenic Oncology Research Group, completed.
Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer is a phase 3 interventional study registered as NCT01985724 by Hellenic Oncology Research Group, with 650 participants recorded, started 2007-10 and reaching its primary completion in 2013-12. Interventions recorded: Docetaxel, Epirubicin, Cyclophosphamide, 5-fluoruracil, Granulocyte-colony stimulating growth factor. Conditions recorded: Breast Cancer.
Linked to the drug Lenograstim because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Hellenic Oncology Research Group, Lenograstim, Pegfilgrastim, Epirubicin and the tag pipeline.
Shares Hellenic Oncology Research Group, Lenograstim, Pegfilgrastim, Epirubicin and the tag pipeline.
Shares Epirubicin, Fluorouracil (5-FU), Docetaxel, Cyclophosphamide and the tag pipeline.
Shares Docetaxel, Cyclophosphamide, Breast cancer (all types) and the tag pipeline.
Shares Epirubicin, Docetaxel and the tag pipeline.
Shares Pegfilgrastim, Docetaxel and the tag pipeline.
Shares Pegfilgrastim, Breast cancer (all types) and the tag pipeline.
Shares Pegfilgrastim, Breast cancer (all types) and the tag pipeline.